Today, we entered into a settlement agreement with @AstraZeneca that includes a binding commitment to provide all #COVID19 vaccines under our contract. We are pleased to have found a mutually satisfactory solution that benefits 🇪🇺 citizens and 🌍 citizens through our global COVAX commitment. Brussels said the shipments would respect an initial purchase agreement concluded by the EU with AstraZeneca a year ago. Tens of millions of doses have already been delivered to EU member states, but not as many as the bloc of 27 countries had planned. Under the agreement, AZ will provide the EU with 200 million vaccines from its vaccine, known as Vaxzevria, by March 2022. That`s the rest of a $300 million supply contract the company signed with the EU last year. Today`s deal appears to settle a bitter dispute that erupted earlier this year, shortly after the UK completely and permanently abandoned EU rules and regulations. AstraZeneca and the European Commission have reached an agreement terminating the legal proceedings relating to the execution of the pre-purchase agreement for the supply of the Vaxzevria COVID-19 vaccine (ChAdOx1-S [Recombinant]). The European Commission, the EU executive, said AstraZeneca had “firmly committed” to delivering a total of 300 million doses by March next year, as agreed as part of the pre-purchase agreement signed a year ago. About 100 million doses have already been delivered.

Pascal Soriot, Chief Executive Officer, said: “This first vaccine agreement with the European Commission will ensure that millions of Europeans have access to the AZD1222 vaccine once it is approved. With the start of production in our European supply chain, we hope to make the vaccine widely and quickly available, with the first doses delivered by the end of 2020. I would like to thank the entire European Commission, and in particular the Commissioner for Health and Food Safety, Stella Kyriakides, for their swift response to ensure that Europeans can soon be protected by a vaccine against this deadly virus that will allow our global society and economy to rebuild. The EU`s executive body said that under the new agreement, member states will receive regular delivery schedules and that if there are delayed doses, capped discounts will be applied. The pre-purchase agreement also provided an option for the provision of additional doses of €100 million, which the Commission has since rejected. In June, a Belgian court ruled that AstraZeneca had committed a “serious breach” of its contract with the 27-nation bloc. The company said at the time that the decision showed it had “fully respected its agreement” with the European Commission. Under the terms of the agreement, AstraZeneca commits to deliver 60 million doses of the vaccine by the end of the third quarter of 2021, 75 million by the end of the fourth quarter of 2021 and 65 million by the end of the first quarter of 2022. Member States shall receive regular delivery schedules and capped discounts shall apply in the case of late doses. 1.

AstraZeneca PLC. The primary phase III analysis AZD1222 US confirms safety and efficacy. Available at: [Last accessed: August 2021] AstraZeneca has reached an agreement with the European Commission (EC) to provide up to 400 million doses of the COVID-19 vaccine AZD1222. Building on the existing agreement with the European Alliance for Inclusive Vaccines, led by Germany, France, Italy and the Netherlands, this new agreement will give all EU Member States the opportunity to access the vaccine equitably and non-profitly during the pandemic. It also allows EU member states to divert cans to other European countries. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a scientifically led global biopharmaceutical company focused on the discovery, development and commercialization of prescription drugs in oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal and metabolic diseases, as well as respiratory tract and immunology. AstraZeneca, based in Cambridge, UK, operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. .